Stille (STIL) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
6 Jun, 2025Executive summary
Q1 2025 saw net sales of MSEK 129.3, down 7.4% year-over-year, due to temporary delivery restrictions and the phase-out of non-strategic products, but demand and order intake remained strong.
Gross margin improved to 51.1% from 48.6% year-over-year, driven by better pricing, favorable geographic mix, and portfolio rationalization.
EBITDA before non-recurring items was MSEK 25.2 (margin 19.5%), down from MSEK 33.7 (24.1%) last year, mainly due to lower sales and higher sales costs.
Cash flow from operating activities improved to MSEK 14.1 from -10.9, reflecting focus on profitability and efficiency.
Earnings per share rose to SEK 1.63 from SEK 1.37 year-over-year.
Financial highlights
Net sales: MSEK 129.3 (139.7), -7.4% year-over-year; organic growth -7.4%.
Gross profit: MSEK 66.0 (67.9); gross margin 51.1% (48.6%).
EBITDA before non-recurring items: MSEK 25.2 (33.7); margin 19.5% (24.1%).
EBIT before non-recurring items: MSEK 17.9 (27.0); margin 13.8% (19.3%).
Net profit: MSEK 14.6 (12.3); EPS SEK 1.63 (1.37).
Outlook and guidance
Strong order intake and operational improvements support confidence in meeting financial targets for 2025.
Full recovery and growth expected in the second half of 2025 as supply chain and capacity measures take effect.
No internal limitations identified for achieving financial targets.
Latest events from Stille
- Q4 sales up 8.5% with strong surgical tables demand; outlook for 2026 remains positive.STIL
Q4 202512 Feb 2026 - Sales rose 8.5% in Q3, but margins fell; supply chain and growth outlook improve for 2026.STIL
Q3 202523 Oct 2025 - Sales declined 12.6% but margin and order intake improved; UK acquisition to boost growth.STIL
Q2 202517 Jul 2025 - Q3 sales surged 82% with margin gains, led by Fehling integration and strong instrument growth.STIL
Q3 202413 Jun 2025 - Net sales nearly doubled in Q2 2024, fueled by Fehling's acquisition and robust organic growth.STIL
Q2 202413 Jun 2025 - Stille AB doubled sales and improved profitability in 2024, focusing on premium surgical solutions.STIL
Q4 20245 Jun 2025